Ysios Capital logo

Ysios Capital

Europe, Pais Vasco, Spain, San Sebastian

Description

Ysios Capital is a leading life sciences investor financing highly innovative companies worldwide

Investor Profile

Ysios Capital has made 72 investments, with 3 in the past 12 months and 33% as lead.

Stage Focus

  • Series A (28%)
  • Series B (28%)
  • Series C (18%)
  • Series Unknown (11%)
  • Series D (7%)
  • Series E (3%)
  • Series F (3%)
  • Series G (1%)
  • Post Ipo Equity (1%)

Country Focus

  • Spain (33%)
  • United States (18%)
  • The Netherlands (17%)
  • Switzerland (10%)
  • Denmark (10%)
  • France (7%)
  • Sweden (3%)
  • United Kingdom (1%)
  • Belgium (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
  • Medical Device
  • Health Diagnostics
  • Life Science
  • Biopharma
  • Hospital
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Ysios Capital frequently co-invest with?

Novartis Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 6
Criteria Venture Tech
Europe, Catalonia, Spain, Barcelona
Co-Investments: 12
Forbion Capital Partners
Europe, Noord-Holland, The Netherlands, Naarden
Co-Investments: 10
Andera Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 9
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 8
Kurma Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 13
HealthCap
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 8
EQT Life Sciences
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 11
Idinvest Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 8
Gilde Healthcare
Europe, Utrecht, The Netherlands, Utrecht
Co-Investments: 14

Which angels does Ysios Capital often collaborate with?

HT
Europe, Noord-Brabant, The Netherlands, Tilburg
Shared Deals: 1

What are some of recent deals done by Ysios Capital?

ADCendo

Copenhagen, Hovedstaden, Denmark

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.

BiotechnologyHealth Care
Series BNov 25, 2024
Amount Raised: $135,000,000
ADCendo

Copenhagen, Hovedstaden, Denmark

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.

BiotechnologyHealth Care
Series AMay 29, 2024
Amount Raised: $17,281,921
Memo Therapeutics

Schlieren, Zurich, Switzerland

Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.

BiotechnologyCollaboration
Series CMay 7, 2024
Amount Raised: $22,015,012
Engrail Therapeutics

San Diego, California, United States

Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.

Health CareLife ScienceMedicalPharmaceutical
Series BMar 19, 2024
Amount Raised: $157,000,000
Neurona Therapeutics

San Francisco, California, United States

Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.

BiotechnologyHealth CareTherapeutics
Series EFeb 8, 2024
Amount Raised: $120,000,000
Kynexis

Naarden, Noord-Holland, The Netherlands

Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).

BiotechnologyHealth CareMedicalTherapeutics
Series ANov 7, 2023
Amount Raised: $60,970,914
Xeltis

Eindhoven, Noord-Brabant, The Netherlands

Xeltis is a clinical-stage medtech company with the world’s most advanced polymer-based platform of restorative cardiovascular devices.

Health CareMedical DeviceTherapeutics
Series DAug 14, 2023
Amount Raised: $13,634,767
Tagworks Pharmaceuticals

Nijmegen, Gelderland, The Netherlands

Tagworks Pharmaceuticals is a privately held biotech company

BiotechnologyHealth CareMedicalPharmaceutical
Series AJun 22, 2023
Amount Raised: $65,000,000
VarmX

Leiden, Zuid-Holland, The Netherlands

VarmX B.V. is manufacturing therapeutic proteins to instantaneously restore blood clotting in bleeding patients.

ManufacturingPharmaceuticalTherapeutics
Series BMay 25, 2023
Amount Raised: $36,950,090
ADCendo

Copenhagen, Hovedstaden, Denmark

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.

BiotechnologyHealth Care
Series AApr 4, 2023
Amount Raised: $33,969,252